Literature DB >> 25035326

Whole-Genome Sequencing of an Isoniazid-Resistant Clinical Isolate of Mycobacterium tuberculosis Strain MtURU-002 from Uruguay.

Luisa Berná1, Gregorio Iraola, Gonzalo Greif1, Cecilia Coitinho2, Carlos M Rivas2, Hugo Naya, Carlos Robello3.   

Abstract

The incidence of tuberculosis in Uruguay has been effectively reduced to <30 per 100,000 population, although an increase in nonrisk populations in the last few years is evident. Here, we present the genome sequence of Mycobacterium tuberculosis strain MtURU-002 isolated from a patient showing bilateral pulmonary tuberculosis that was resistant to isoniazid.
Copyright © 2014 Berná et al.

Entities:  

Year:  2014        PMID: 25035326      PMCID: PMC4102863          DOI: 10.1128/genomeA.00655-14

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Tuberculosis (TB), caused by infection with Mycobacterium tuberculosis, constitutes a major cause of morbidity and mortality worldwide, ranking as the second leading cause of death from a single infectious agent, after human immunodeficiency virus. In Uruguay, the National Tuberculosis Program has effectively reduced the incidence of TB to <30 per 100,000 population, with 600 to 700 new cases per year (data available at the World Health Organization Web page [http://www.who.int/]). However, in the last 5 years, there has been an increase in TB incidence not only in high-risk populations (patients with human immunodeficiency virus and TB coinfection, those in poverty, and prisoners) but also in nonrisk populations, such as in our recent report of 11 cases of well-nourished young subjects affected by the disease (1). In this context, the whole-genome study of isolates from different populations (high- and low-risk) becomes a necessity in order to perform future comparative genomic studies and to determine new molecular markers of pathogenicity and transmissibility, among other aims. In this work, we performed the complete genome sequencing of a clinical isolate from a patient showing bilateral pulmonary tuberculosis that was resistant to isoniazid. Sequencing was performed at the Institut Pasteur de Montevideo on an Illumina platform. A total of 1,496,856 paired-end reads (2 × 100 cycles) were generated; the reads were corrected using AllPaths-LG (2), and then Velvet (3) software was used for the de novo assembly. A total of 169 contigs were found, with an average coverage of 69-fold. Using the reference genome of M. tuberculosis H37Rv (accession no. NC_000962), the assembly quality was further improved through the PAGIT toolkit (4) and evaluated with the Assembly Likelihood Estimator (ALE) software (5). Finally, automatic annotation was performed using RAST (6). M. tuberculosis strain MtURU-002 has a total of 4,324,103 bp, with an average G+C content of 63%. It contains 4,328 predicted coding sequences (CDSs), 1 rRNA operon, and 45 tRNA genes. Single nucleotide polymorphisms versus M. tuberculosis H37Rv were identified using BWA (7) and the GATK pipeline (8). A total of 540 single nucleotide polymorphisms (SNPs) and 35 indels were found. Of them, 482 belong to coding sequences, and 8 introduce stop codons disrupting membrane protein-related genes involved in lipid metabolism or cell wall processes. As mentioned, drug sensitivity analysis revealed the isolate to be resistant to isoniazid. Remarkably, we did not identify any reported mutation related to this resistance (https://tbdreamdb.ki.se). However, we found a novel mutation, G471S, in the iniB gene (isoniazid inducible gene) that might explain resistance. Further studies should be done to evaluate the ability of the iniB gene to confer isoniazid resistance

Nucleotide sequence accession number.

This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession no. JNGE00000000.
  8 in total

1.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

2.  Velvet: algorithms for de novo short read assembly using de Bruijn graphs.

Authors:  Daniel R Zerbino; Ewan Birney
Journal:  Genome Res       Date:  2008-03-18       Impact factor: 9.043

3.  Rapidly progressing tuberculosis outbreak in a very low risk group.

Authors:  Cecilia Coitinho; Gonzalo Greif; Carlos Robello; Paula Laserra; Eve Willery; Philip Supply
Journal:  Eur Respir J       Date:  2013-10-10       Impact factor: 16.671

4.  ALE: a generic assembly likelihood evaluation framework for assessing the accuracy of genome and metagenome assemblies.

Authors:  Scott C Clark; Rob Egan; Peter I Frazier; Zhong Wang
Journal:  Bioinformatics       Date:  2013-01-09       Impact factor: 6.937

5.  A post-assembly genome-improvement toolkit (PAGIT) to obtain annotated genomes from contigs.

Authors:  Martin T Swain; Isheng J Tsai; Samual A Assefa; Chris Newbold; Matthew Berriman; Thomas D Otto
Journal:  Nat Protoc       Date:  2012-06-07       Impact factor: 13.491

6.  ALLPATHS: de novo assembly of whole-genome shotgun microreads.

Authors:  Jonathan Butler; Iain MacCallum; Michael Kleber; Ilya A Shlyakhter; Matthew K Belmonte; Eric S Lander; Chad Nusbaum; David B Jaffe
Journal:  Genome Res       Date:  2008-03-13       Impact factor: 9.043

7.  Fast and accurate long-read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2010-01-15       Impact factor: 6.937

8.  The RAST Server: rapid annotations using subsystems technology.

Authors:  Ramy K Aziz; Daniela Bartels; Aaron A Best; Matthew DeJongh; Terrence Disz; Robert A Edwards; Kevin Formsma; Svetlana Gerdes; Elizabeth M Glass; Michael Kubal; Folker Meyer; Gary J Olsen; Robert Olson; Andrei L Osterman; Ross A Overbeek; Leslie K McNeil; Daniel Paarmann; Tobias Paczian; Bruce Parrello; Gordon D Pusch; Claudia Reich; Rick Stevens; Olga Vassieva; Veronika Vonstein; Andreas Wilke; Olga Zagnitko
Journal:  BMC Genomics       Date:  2008-02-08       Impact factor: 3.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.